Interventions for American cutaneous and mucocutaneous leishmaniasis

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 8, 2020, Pages

  Pinart, Mariona ^a   Rueda, José Ramón ^b   Romero, Gustavo AS ^c   Pinzón Flórez, Carlos Eduardo ^d   Osorio Arango, Karime ^e   Silveira Maia Elkhoury, Ana Nilce ^f   Reveiz, Ludovic ^g   Elias, Vanessa M ^g   Tweed, John A ^h  

^a Free time independent Cochrane reviewer   (Germany)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c UNIVERSITY OF BRASILIA   (Brazil)

^d Keralty   (Colombia)

^e INSTITUTO NACIONAL DE SALUD   (Colombia)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g PAN AMERICAN HEALTH ORGANIZATION   (United States)

^h UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE; AMPHOTERICIN B; ANTHELMINTIC AGENT; ANTIMONY; AZITHROMYCIN; FLUCONAZOLE; GAMMA INTERFERON; GENTAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; NITRIC OXIDE; ORAL REHYDRATION SOLUTION; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PENTOXIFYLLINE; PLACEBO; STIBOGLUCONATE SODIUM; TAMOXIFEN; ANTIPROTOZOAL AGENT; BCG VACCINE; LEISHMANIA VACCINE; PHOSPHORYLCHOLINE;

ARTHRALGIA; CLINICAL OUTCOME; COMPARATIVE STUDY; CRYOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; HISTOPATHOLOGY; HUMAN; LEISHMANIA AMAZONENSIS; LEISHMANIA BRAZILIENSIS; LEISHMANIA GUYANENSIS; LEISHMANIA MEXICANA; LEISHMANIA PANAMENSIS; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SKIN LEISHMANIASIS; SYSTEMATIC REVIEW; THERMOTHERAPY; TREATMENT DURATION; ADMINISTRATION AND DOSAGE; ADULT; ADVERSE EVENT; FEMALE; IMMUNOCOMPETENCE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, ORAL; ADULT; ANTIPROTOZOAL AGENTS; AZITHROMYCIN; BCG VACCINE; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; IMMUNOCOMPETENCE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; INTERFERON-GAMMA; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, MUCOCUTANEOUS; MALE; MEGLUMINE ANTIMONIATE; PENTOXIFYLLINE; PHOSPHORYLCHOLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85089943510     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004834.pub3     Document Type: Review

References (270)

1. Almeida R, D'Oliveira A Jr, Machado P, Bacellar O, Ko AI, de Jesus AR, et al. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis. Journal of Infectious Diseases 1999;180(5):1735-7. [CENTRAL: CN-00266553] x-wiley/crsRef/3230715
2. Alves FHC, E Silva JSF, De Araujo Pereira LI, De Paula CDR, Ribeiro RN, Gomes CM, et al. The efficacy of pentamidine in comparison to pentavalent antimonial in American tegumentary leishmaniasis: an open label, randomized, controlled trial. Journal of the American Academy of Dermatology 2016;74(5 Suppl 1):AB155. [CENTRAL: CN-01160654] x-wiley/crsRef/14402727
3. Alves Norões IJ, Moraes MO, Silva Feitosa TT, Bonilha de Souza LS, Gonçalves Júnior J, Rolim-Neto ML, et al. Avaliation the therapeutic efficacy of fluconazol. International Archives of Medicine 2015;8(135):1-16. x-wiley/crsRef/14402729 [DOI: 10.3823/1734]
4. Lima da Silva CG. Avaliaçao da eficácia terapêutica do fluconazol na leishmaniose tegumentar humana [Doctoral hesis]. Faculdade de Medicina, Fortaleza, Brazil: Universidade Federal do Ceará, 2012. x-wiley/crsRef/14402730
5. Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, Luz-Cjuno M, Echevarria J, Miranda-Verasategui C, et al. Comparison of meglumine and pentamidine for Peruvian cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2005;72(2):133-7. [CENTRAL: CN-00502527] x-wiley/crsRef/3230717
6. Arana BA, Navin TR, Arana FE, Berman JD, Rosenkaimer F. Efficacy of a short course (10 days) of high-dose meglumine antimoniate with or without Interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clinical Infectious Diseases 1994;18(3):381-4. [CENTRAL: CN-00102358] x-wiley/crsRef/3230719
7. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with the paromomycin plus methylbenzethonium chloride ointment in Guatemala. American Journal of Tropical Medicine and Hygiene 2001;65(5):466-70. [CENTRAL: CN-00375557] x-wiley/crsRef/3230721
8. Arévalo I, Tulliano G, Quispe A, Spaeth G, Mathlashewski, Llanos-cuantas A, et al. Role of imiquimod and parenteral meglumine antimoniate in the intitial treatment of cutaneous lesihmaniasis. Clinical Infectious Diseases 2007;44(12):1549-54. [CENTRAL: CN-00589061] x-wiley/crsRef/3230723
9. Armijos RX, Weigel MM, Calvopiña M, Mancheno M, Rodriguez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Tropica 2004;91(2):153-60. [CENTRAL: CN-00480899] x-wiley/crsRef/3230725
10. Ballou WR, McClain JB, Gordon DM, Dhanks GD, Adujar J, Berman JD, et al. Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet 1987;4(8549):13-6. [CENTRAL: CN-00048758] x-wiley/crsRef/14402732
11. Brito G, Dourado M, Polari L, Celestino D, Carvalho LP, Queiroz A, et al. Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. American Journal of Tropical Medicine and Hygiene 2014;90(4):617-20. [CENTRAL: CN-00984312] x-wiley/crsRef/14402734
12. Brito G, Dourado M, Guimaraes L, Meireles E, Schriefer A, Carvalho E, et al. Oral pentoxifylline associated with pentavalent antimony: a randomized trial for cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2017;96(5):1155-9. [CENTRAL: CN-01373250] x-wiley/crsRef/14402736
13. Chico M, Armijos R, Racines J, Mancero T, Guderian RH. Evaluation of allopurinol-riboside therapy against Ecuadorian cutaneous leishmaniasis [Evaluación del ribósido de alpurinol contra la leishmaniasis cutánea ecuatoriana]. Biomedica 1995;15(3):116-22. x-wiley/crsRef/14402738 [DOI: 10.7705/biomedica.v15i3.868]
14. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, Da Silva RM, Gadelha Yamashita EP, De Oliveira Penna G, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. American Journal of Tropical Medicine and Hygiene 2011;84(2):255-60. [CENTRAL: CN-00778313] x-wiley/crsRef/14402740
15. Convit J, Castellanos PL, Rondon A, Pinardi ME, Ulrich M, Castes M, et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1987;21(8530):401-5. [CENTRAL: CN-00046375] x-wiley/crsRef/3230729
16. Convit J, Castellanos PL, Ulrich M, Castés M, Rondón A, Pinardi ME, et al. Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. Journal of Infectious Diseases 1989;160(1):104-15. [CENTRAL: CN-00060507] x-wiley/crsRef/3230731
17. Correia D, Macêdo VO, Carvalho EM, Barral A, Magalhâes AV, De Abreu MV, et al. Comparative study of meglumine antimoniate, pentamidine isothionate and aminosidine sulphate in the treatment of primary skin lesions caused by Leishmania (viannia) braziliensis. Revista da Sociedade Brasilera de Medicina Tropical 1996;29(5):447-53. [CENTRAL: CN-00132502] x-wiley/crsRef/3230733
18. Cossio-Duque A, Mar CM, Navas A, Valderrama L, Cuervo-Pardo L, Marquez R, et al. Effect of the addition of pentoxifylline on the therapeutic and inflammatory response in patients with cutaneous leishmaniasis: a randomized placebo controlled trial. Frontiers 2015;93(4 Suppl):536. [CENTRAL: CN-01249729] x-wiley/crsRef/14402742
19. D'Oliveira A Jr, Machado PR, Carvalho EM. Evaluating the efficacy of allopurinol for treatment of cutaneous leishmaniasis. International Journal of Dermatology 1997;36(12):938-40. [CENTRAL: CN-00147570] x-wiley/crsRef/3230735
20. Echevarria J, Seas C, Cruz M, Chavez E, Campos M, Cieza J, et al. Oral rehydration solution to prevent nephrotoxicity of amphotericin B. American Journal of Tropical Medicine and Hygiene 2006;75(6):1108-12. [CENTRAL: CN-00577315] x-wiley/crsRef/14402744
21. Ferreira Terceiro BR. Comparação entre o esquema padrão e alternativo de antimoniato de meglumina no tratamento da leishmaniose mucocutânea ou mucosa [Comparison of the standard scheme and alternative meglumine antimoniate in the treatment of leishmaniasis mucocutaneous or mucosal] [Masters thesis]. Rio de Janeiro: Instituto Nacional de Infectologia Evandro Chagas, 2014. x-wiley/crsRef/14402746 [lil-751645]
22. Figueiredo Kopke LF, Siviero do Vale EC, Grossi Araujo M, Araújo Magalhâes P, Furtado T. Treatment of American cutaneous leishmaniasis by N-methyl-glucamine. Double-blind study with dosages of 14 mg/kg/day and 28 mg/kg/day of antimony [Tratamento da leishmaniose tegumentar americana pelo antimoniato de N-metil-glucamina: Estudo duplo-cego com doses de 14 mg/kg/dia e 28 mg/kg/dia de antimônio]. Anais Brasileiros de Dermatologia 1991;66(2):87-94. [CENTRAL: CN-00187782] x-wiley/crsRef/3230737 [EMBASE: 21169232]
23. Franke ED, Llanos-Cuentas A, Echevarria J, Cruz ME, Campos P, Tovar AA, et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (pentostam) in the treatment of mucosal leishmaniasis. American Journal of Tropical Medicine and Hygiene 1994;51(1):77-82. [CENTRAL: CN-00103648] x-wiley/crsRef/3230739
24. Gadelha EP, Ramasawmy R, Da Costa Oliveira B, Morais Rocha N, De Oliveira Guerra JA, Allan Villa Rouco da Silva G, et al. An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region. PLOS Neglected Tropical Diseases 2018;12(10):e0006850. x-wiley/crsRef/14402748
25. Garcia Bustos MF, Barrio A, Parodi C, Beckar J, Moreno S, Basombrio MA. Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis. Medicina 2014;74(5):371-7. [CENTRAL: CN-01089869] x-wiley/crsRef/14402750
26. Guderian RH, Chico ME, Rogers MD, Pattishall KM, Grogl M, Berman JD. Placebo controlled treatment of Ecuadorian cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 1991;45(1):92-7. [CENTRAL: CN-00077349] x-wiley/crsRef/3230741
27. Guzman-Rivero M, Rojas E, Verduguez-Orellana A, Pardo H, Torrico MC, Cloetens L, et al. Nutritional status in patients with cutaneous leishmaniasis and a study of the effects of zinc supplementation together with antimony treatment. Food & Nutrition Research 2014;58:23353. [CENTRAL: CN-01072233] x-wiley/crsRef/14402752 [DOI: 10.3402/fnr.v58.23353]
28. Hepburn NC, Tidman MJ, Hunter JA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994;88(6):700-3. [CENTRAL: CN-00111782] x-wiley/crsRef/3230743
29. Hu RV, Straetemans M, Kent AD, Sabajo LO, De Vries HJ, Fat RF. Randomized single-blinded non-inferiority trial of 7 mg/kg pentamidine isethionate versus 4 mg/kg pentamidine isethionate for cutaneous leishmaniaisis in Suriname. PLOS Neglected Tropical Diseases 2015;9(3):e0003592. [CENTRAL: CN-01256791] x-wiley/crsRef/14402754
30. Krolewiecki AJ, Romero HD, Cajal SP, Abraham D, Mimori T, Matsumoto T, et al. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. American Journal of Tropical Medicine and Hygiene 2007;77(4):640-6. [CENTRAL: CN-00620647] x-wiley/crsRef/3230827
31. Llanos-Cuentas A, Echevarria J, Cruz M, La Rosa A, Campos P, Campos M, et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clinical Infectious Diseases 1997;25(3):677-84. [CENTRAL: CN-00143908] x-wiley/crsRef/3230745
32. Llanos-Cuentas A, Echevarria J, Seas C, Chang E, Cruz M, Alvarez E, et al. Parenteral aminosidine is not effective for peruvian mucocutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2007;76(6):1128-31. [CENTRAL: CN-00703926] x-wiley/crsRef/3230747
33. Lobo IM, Soares MB, Correia TM, De Freitas LA, Oliveira MI, Nakatani M, et al. Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006;100(7):642-9. [CENTRAL: CN-00561435] x-wiley/crsRef/3230749
34. López L, Vélez I, Asela C, Cruz C, Alves F, Robledo S, et al. A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia. PLOS Neglected Tropical Disiseases 2018;12(7):e0006653. x-wiley/crsRef/14402756
35. Lopez-Jaramillo P, Rincon MY, Garcia RG, Silva SY, Smith E, Kampeerapappun P, et al. A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensis. American Journal of Tropical Medicine and Hygiene 2010;83(1):97-101. [CENTRAL: CN-00749347] x-wiley/crsRef/14402758
36. Machado PR, Lessa H, Lessa M, Guimaraes LH, Bang H, Ho JL, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clinical Infectious Diseases 2007;44(6):788-93. [CENTRAL: CN-00578520] x-wiley/crsRef/3230751
37. Machado PR, Ampuero J, Guimaraes LH, Schriefer A, Carvalho EM, Talhari S, et al. Efficacy of miltefosine in the treatment of American cutaneous leishmaniasis caused by leishmania braziliensis in Brazil. PLOS Neglected Tropical Diseases 2010;4(12):e912. x-wiley/crsRef/14402760 [DOI: 10.4269/ajtmh.2009.81.201]
38. Machado PR, Ribeiro CS, França-Costa J, Dourado ME, Trinconi CT, Yokoyama-Yasunaka JK, et al. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial. Tropical Medicine & International Health 2018;23(9):936-42. x-wiley/crsRef/14402762
39. Machado-Pinto J, Pinto J, Da Costa CA, Genaro O, Marques MJ, Modabber F, et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. International Journal of Dermatology 2002;41(2):73-8. [CENTRAL: CN-00389013] x-wiley/crsRef/3230753
40. Martínez S, Marr J. Allopurinol in the treatment of American cutaneous leishmaniasis. New England Journal of Medicine 1992;326(11):741-4. [CENTRAL: CN-00081583] x-wiley/crsRef/3230755
41. Martínez S, Gonzalez M, Vernaza ME. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clinical Infectious Diseases 1997;24(2):165-9. [CENTRAL: CN-00138905] x-wiley/crsRef/3230757
42. Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clinical Infectious Diseases 2005;40(10):1395-403. [CENTRAL: CN-00560657] x-wiley/crsRef/14402764
43. Miranda-Verástegui C, Tulliano G, Gyorkos TW, Calderon W, Rahme E, Ward B, et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLOS Neglected Tropical Diseases 2009;3(7):e491. [CENTRAL: CN-00729032] x-wiley/crsRef/14402766
44. Navin TR, Arana BA, Arana FE, De Mérida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimoniate (glucantime) versus localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. American Journal of Tropical Medicine and Hygiene 1990;42(1):43-50. [CENTRAL: CN-00065499] x-wiley/crsRef/3230761
45. Navin TR, Aran BA, Arana FE, Berman JD, Chajón JF. Placebo-controlled clinical trial of sodium stibogluconate (pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. Journal of Infectious Diseases 1992;165(3):528-34. [CENTRAL: CN-00081938] x-wiley/crsRef/3230763
46. NCT01011309. A study of the efficacy and safety of the LEISH-F2 + MPL-SE vaccine for treatment of cutaneous leishmaniasis [A phase 2, randomized, open-label, controlled study to evaluate the efficacy, safety, and immunogenicity of the LEISH-F2 + MPL-SE vaccine in the treatment of patients with cutaneous leishmaniasis]. clinicaltrials.gov/ct2/show/study/NCT01011309 (first received 11 November 2009). x-wiley/crsRef/14402768
47. Neva FA, Ponce C, Ponce E, Kreutzer R, Modabber F, Olliaro P. Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin. Transactions of the Royal Society of Tropical Medicine and Hygiene 1997;91(4):473-5. [CENTRAL: CN-00145412] x-wiley/crsRef/3230765
48. Neves LO, Talhari AC, Gadelha EP, Silva Junior RM, Guerra JA, Ferreira LC, et al. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. Anais Brasileiros de Dermatologia 2011;86(6):1092-101. [CENTRAL: CN-00842795] x-wiley/crsRef/14402770
49. Newlove T, Guimaraes LH, Morgan DJ, Alcantara L, Glesby MJ, Carvalho EM, et al. Antihelminthic therapy and antimony in cutaneous leishmaniasis: a randomized, double-blind, placebo-controlled trial in patients co-infected with helminths and Leishmania braziliensis. American Journal of Tropical Medicine and Hygiene 2011;84(4):551-5. [CENTRAL: CN-00788444] x-wiley/crsRef/14402772
50. Oliveira-Neto MP, Schubach A, Mattos M, Gonçalves-Costa SC, Pirmez C. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens [Traitement de la leishmanoise cutanee americaine: une comparison entre faible dose (5mg/kg/jour) et haute dose (20mg/kg/jour) d'antimoine]. Pathologie-biologie 1997;45(6):496-9. [CENTRAL: CN-00254046] x-wiley/crsRef/3230767
51. Oster CN, Chulay JD, Hendricks LD, Pamplin CL III, Ballou WR, Berman JD, et al. American cutaneous leishmaniasis: a comparison of three sodium stibogluconate treatment schedules. American Journal of Tropical Medicine and Hygiene 1985;34(5):856-60. [CENTRAL: CN-00039556] x-wiley/crsRef/3230769
52. Palacios R, Osorio LE, Grajales LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimoniate for cutaneous leishmaniasis due to leishmania viannia species. American Journal of Tropical Medicine and Hygiene 2001;64(3-4):187-93. [CENTRAL: CN-00349275] x-wiley/crsRef/3230771
53. Prates FV, Dourado ME, Silva SC, Schriefer A, Guimarães LH, Brito MD, et al. Fluconazole in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis: a randomized controlled trial. Clinical Infectious Diseases 2017;64(1):67-71. [CENTRAL: CN-01444134] x-wiley/crsRef/14402774
54. Ravis WR, Llanos-Cuentas A, Sosa N, Kreishman-Deitrick M, Kopydlowski KM, Nielsen C, et al. Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis. Antimicrobial Agents and Chemotherapy 2013;57(10):4809-15. [CENTRAL: CN-00916363] x-wiley/crsRef/14402776
55. Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodríguez-Barraquer I, Garcerant D, et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. Journal of Infectious Diseases 2012;205(4):684-92. [CENTRAL: CN-00814449] x-wiley/crsRef/14402778
56. Saenz RE, Paz HM, Johnson CM, Narvaez E, De Vasquez AM. Evaluation of the effectiveness and toxicity of pentostam and glucantime in the treatment of cutaneous leishmaniasis [Evaluación de la effectividad y toxicidad del pentostam y del glucantime en el tratamiento de la leishmaniasis cutanea]. Revista Médica de Panamá 1987;12(3):148-57. [CENTRAL: CN-01139764] x-wiley/crsRef/3230773
57. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against leishmania braziliensis panamensis cutaneous leishmaniasis. American Journal of Medicine 1990;89(2):147-55. [CENTRAL: CN-00069419] x-wiley/crsRef/3230775
58. Lyra MR. Phase III clinical trial for American cutaneous leishmaniasis. Equivalence between high and low dose schemes of meglumine antimoniate [Masters thesis] [Ensaio clínico fase iii para leishmaniose tegumentar americana forma cutânea. Equivalência entre esquemas de alta e baixa dose de antimoniato de meglumina]. www.arca.fiocruz.br/handle/icict/14378 (accessed prior to 1 February 2019). x-wiley/crsRef/14402780
59. Ribeiro MN, Pimentel MI, Schubach Ade O, Oliveira R de V, Teixeira JL, Leite MP, et al. Factors associated with adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis. Revista do Instituto de Medicina Tropical de Sao Paulo 2014;56(4):291-6. x-wiley/crsRef/14402781
60. Saheki MN, Lyra MR, Bedoya-Pacheco SJ, Antonio LF, Pimentel MIF, Salgueiro MM, et al. Low versus high dose of antimony for American cutaneous leishmaniasis: a randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil. PLOS One 2017;12(5):e0178592. [CENTRAL: CN-01413190] x-wiley/crsRef/14402782
61. Saheki MN. A randomized, controlled, single blind, non-inferiority trial of low dose versus high dose meglumine antimoniate for American cutaneous leishmaniasis in Rio de Janeiro, Brazil [Masters thesis] [Ensaio clínico de não inferioridade, randomizado, controlado, cego,de antimoniato de meglumina em dose baixa versus dose alta paraleishmaniose cutânea americana no Rio de Janeiro, Brasil]. www.arca.fiocruz.br/handle/icict/12458 (accessed prior to 1 February 2019). x-wiley/crsRef/14402783
62. Sampaio RN, Silva Jsfe, Paula CD, Porto C, Motta Jocd, Pereira LI, et al. A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical 2019;52:e20180292. x-wiley/crsRef/14402785
63. Santos JB, De Jesus AR, Machado PR, Magalhâes A, Salgado K, Carvalho EM, et al. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. Journal of Infectious Diseases 2004;190(10):1793-6. [CENTRAL: CN-00492355] x-wiley/crsRef/3230777
64. Sosa N, Capitan Z, Nieto J, Nieto M, Calzada J, Paz H, et al. Randomized, double-blinded, phase 2 trial of wr 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. American Journal of Tropical Medicine and Hygiene 2013;89(3):557-63. [CENTRAL: CN-00876215] x-wiley/crsRef/14402787
65. NCT01790659. Phase 3 study of Walter Reed (WR) 279,396 and paromomycin alone for the treatment of cutaneous leishmaniasis in Panama [A randomized, double-blind, pivotal phase 3 study of WR 279,396 (paromomycin + gentamicin topical cream) and paromomycin alone topical cream for the treatment of cutaneous leishmaniasis in Panama]. clinicaltrials.gov/ct2/show/study/NCT01790659 (first received 13 February 2013). x-wiley/crsRef/14402789
66. Sosa N, Pascale JM, Jimenez AI, Norwood JA, Kreishman-Detrick M, Weina PJ, et al. Topical paromomycin for New World cutaneous leishmaniasis. PLOS Neglected Tropical Diseases 2019;13(5):e0007253. x-wiley/crsRef/14402790
67. Soto J, Grogl M, Berman J, Olliaro P. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994;88(6):695-8. [CENTRAL: CN-00111780] x-wiley/crsRef/14402792
68. Soto J, Fuya P, Herrera R, Berman J. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimoniate as treatment for American cutaneous leishmaniasis: controlled study. Clinical Infectious Diseases 1998;26(1):56-8. [CENTRAL: CN-00147306] x-wiley/crsRef/3230781
69. Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. American Journal of Tropical Medicine and Hygiene 2002;66(2):147-51. [CENTRAL: CN-00390421] x-wiley/crsRef/3230783
70. Soto J, Valda-Rodriguez L, Toledo J, Vera-Navarro L, Luz M, Monasterios-Torrico H, et al. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2004;71(5):577-81. [CENTRAL: CN-00504004] x-wiley/crsRef/3230785
71. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Diseases 2004;38(9):1266-72. [CENTRAL: CN-00470183] x-wiley/crsRef/3230787
72. Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2008;78(2):210-1. [CENTRAL: CN-00629911] x-wiley/crsRef/3230829
73. Soto J, Rojas E, Guzman M, Verduguez A, Nena W, Maldonado M, et al. Intralesional antimony for single lesions of Bolivian cutaneous leishmaniasis. Clinical Infectious Diseases 2013;56(9):1255-60. [CENTRAL: CN-00877427] x-wiley/crsRef/14402794
74. Soto J, Paz D, Rivero D, Soto P, Quispe J, Toledo J, et al. Intralesional pentamidine: a novel therapy for single lesions of Bolivian cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2016;94(4):852-6. [CENTRAL: CN-01154109] x-wiley/crsRef/14402796
75. Soto J, Paz D, Rivero D, Soto P, Quispe J, Toledo J, et al. Intralesional pentamidine: a novel therapy for single lesions of Bolivian cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2016;94(4):852-6. [CENTRAL: CN-01154109] x-wiley/crsRef/14402798
76. Soto J, Soto P, Ajata A, Luque C, Tintaya C, Paz D, et al. Topical 15% paromomycin-aquaphilic for Bolivian leishmania braziliensis cutaneous leishmaniasis: a randomized, placebo-controlled trial. Clinical Infectious Diseases 2019;68(5):844-9. x-wiley/crsRef/14402800
77. Souza e Souza I, Lima IC, Alecrim JF. American cutaneous leishmaniasis: therapeutic study of pentamidine isotionate versus N-metil-glucantime. Journal of the European Academy of Dermatology and Venereology: JEADV 1998;11(Suppl 2):S153. x-wiley/crsRef/14402802
78. Toledo Junior A, Daher AB, Amaral TA, Carvalho SF, Romero GA, Rabello A. Poor response to azithromycin in cutaneous leishmaniasis leading to a premature interruption of a multicentric phase III clinical trial in Brazil. Revista Da Sociedade Brasileira de Medicina Tropical 2014;47(6):756-62. [CENTRAL: CN-01048573] x-wiley/crsRef/14402804
79. Vélez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis: a randomized, controlled trial. Annals of Internal Medicine 1997;126(3):232-6. [CENTRAL: CN-00135976] x-wiley/crsRef/3230789
80. López L, Cruz C, Godoy G, Robledo SM, Vélez ID. Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia. Revista do Instituto de Medicina Tropical de Sao Paulo 2013;55(3):S0036-46652013000300197. x-wiley/crsRef/14402806
81. López L, Robayo M, Vargas M, Vélez ID. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials 2012;13:58. x-wiley/crsRef/14402807
82. Vélez I, Lopez L, Sanchez X, Mestra L, Rojas C, Rodriguez E. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2010;83(2):351-6. [CENTRAL: CN-00760206] x-wiley/crsRef/14402808
83. Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, Correa J. Safety, immunogeneicity, and efficacy of an autoclaved leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 2004;22(9-10):1320-6. [CENTRAL: CN-00471149] x-wiley/crsRef/3230791
84. De Luca PM, Mayrink W, Alves CR, Coutinho SG, Oliveira MP, Bertho AL, et al. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine 1999;17(9-10):1179-85. [CENTRAL: CN-00305330] x-wiley/crsRef/3230793
85. De Luca PM, Mayrink W, Pinto JA, Coutinho SG, Santiago MA, Toledo VP, et al. A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis. Acta Tropica 2001;80(3):251-60. [CENTRAL: CN-00375249] x-wiley/crsRef/3230795
86. De Luca PM, Mayrink W, Santiago MA, Nogueira R, Conceição-Silva F, Mélo G, et al. Randomized, double-blind, placebo-controlled study on the immunogenicity of the leishmanin skin test. Transactions of the Royal Society of Tropical Medicine and Hygiene 2003;97(6):709-12. [CENTRAL: CN-00551996] x-wiley/crsRef/3230797
87. Deps PD, Viana MC, Falqueto A, Dietze R. Evaluation of the efficacy and toxicity of N-methyl-glucamine vs BP88 Sodium Stibogluconate in the treatment of localized cutaneous leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical 2000;33(6):535-43. [CENTRAL: CN-00399871] x-wiley/crsRef/3230799
88. Fagundes A, Marzochi MC, Perez M, Schubach A, Ferreira A, Silva JP, et al. Skin reactivity to thimerosal and phenol-preserved Montenegro antigen in Brazil. Acta Tropica 2007;101(1):25-30. [CENTRAL: CN-00577747] x-wiley/crsRef/3230801
89. Falquete A, Sessa AP. Leishmaniose tegumentar americana. In: Veronesi R, Focaccia R, editors(s). Tratado de infectologia. Sâo Paulo: Atheneu, 2002:1241-53. x-wiley/crsRef/14402810
90. Gardlo K, Horska Z, Enk CD, Rauch L, Megahed M, Ruzicka T, et al. Treatment of cutaneous leishmaniasis by photodynamic therapy. Journal of the American Academy of Dermatology 2003;48(6):893-6. [CENTRAL: CN-00466020] x-wiley/crsRef/14402812
91. Hendrickx EP, Agudelo SP, Munoz DL, Puerta JA, Velez Bernal ID. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. American Journal of Tropical Medicine and Hygiene 1998;59(6):889-92. x-wiley/crsRef/14402814 [PMID: 9886195]
92. Hepburn NC, Tidman MJ, Hunter JA. Cutaneous leishmaniasis in British troops from Belize. British Journal of Dermatology 1993;128(1):63-8. x-wiley/crsRef/14402816 [PMID: 8381299]
93. Hepburn NC, Siddique I, Howie AF, Beckett GJ, Hayes PC. Hepatotoxicity of sodium stibogluconate therapy for American cutaneous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994;88(4):453-5. [CENTRAL: CN-00119186] x-wiley/crsRef/3230803
94. Herwaldt BL, Arana BA, Navin TR. The natural history of cutaneous leishmaniasis in Guatemala. Journal of Infectious Diseases 1992;165(3):518-27. x-wiley/crsRef/14402818 [PMID: 1538157]
95. Krause G, Kroeger A. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study. Clinical Infectious Diseases 1999;29(2):466-7. x-wiley/crsRef/14402820 [PMID: 10476776]
96. Laguna-Torres VA, Silva CA, Correia D, Carvalho EM, Magalhâes AV, De Oliveira Macêdo V. Efficacy of mefloquine in the treatment of skin leishmaniasis in an endemic area of leishmania (viannia) braziliensis. Revista da Sociedade Brasileira de Medicina Tropical 1999;32(5):529-32. [CENTRAL: CN-00414710] x-wiley/crsRef/3230805
97. Llanos A, Cieza J, Bernardo J, Echevarria J, Biaggioni I, Sabra R, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney International 1991;40(2):302-8. [CENTRAL: CN-00079305] x-wiley/crsRef/3230807
98. Llanos-Cuentas A, Calderon W, Cruz M, Ashman JA, Alves FP, Coler RN, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 2010;28(46):7427-35. [CENTRAL: CN-00768896] x-wiley/crsRef/14402822
99. Monjour L, Neogy AB, Vouldoukis I, Silva OA, Boisnic S, Brito ME, et al. Exploitation of parasite derived antigen in therapeutic success of human cutaneous leishmaniasis in Brazil. Memórias do Instituto Oswaldo Cruz 1994;89(3):479-83. [CENTRAL: CN-00118323] x-wiley/crsRef/3230809
100. Motta JO, Sampaio RN. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. Journal of the European Academy of Dermatology and Venereology: JEADV 2012;26(3):331-5. [CENTRAL: CN-00882917] x-wiley/crsRef/14402824
101. Nascimento E, Mayrink W, Da Costa CA, Michalick MS, Melo MN, Barros GC, et al. Vaccination of humans against cutaneous leishmaniasis: cellular and humoral inmune responses. Infection and Immunity 1990;58(7):2198-203. [CENTRAL: CN-00068740] x-wiley/crsRef/3230811
102. Oliveira-Neto MP, Mattos M, Primez C, Fernandes O, Gonçalves-Costa SC, Souza CF, et al. Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucantime in Rio de Janeiro, Brazil. Revista do Instituto de Medicina Tropical de São Paulo 2000;42(6):321-5. [CENTRAL: CN-00372731] x-wiley/crsRef/3230813
103. Rodriguez LV, Dedet JP, Paredes V, Mendoza C, Cardenas F. A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis. Memórias do Instituto Oswaldo Cruz 1995;90(4):525-8. [CENTRAL: CN-00121054] x-wiley/crsRef/3230815
104. Saldanha AC, Romero GA, Guerra C, Merchan-Hamann E, Macedo Vde O. Comparative study between sodium stibogluconate BP 88 and meglumine antimoniate in cutaneous leishmaniasis treatment. II. Biochemical and cardiac toxicity. Revista da Sociedade Brasileira de Medicina Tropical 2000;33(4):383-8. x-wiley/crsRef/14402826 [PMID: 10936953]
105. Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. American Journal of Tropical Medicine and Hygiene 1994;50(1):107-11. [CENTRAL: CN-00098861] x-wiley/crsRef/14402828
106. Soto J, Hernandez N, Mejia H, Grogl M, Berman J. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clinical Infectious Diseases 1995;20(1):47-51. [CENTRAL: CN-00113359] x-wiley/crsRef/14402830
107. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clinical Infectious Diseases 1993;16(3):417-25. [CENTRAL: CN-00091785] x-wiley/crsRef/14402832
108. Urcuyo FG, Zaias N. Oral ketoconazole in the treatment of leishmaniasis. International Journal of Dermatology 1982;21(7):414-6. x-wiley/crsRef/14402834 [PMID: 6290403]
109. Veiga JP, Rosa TT, Kimachi T, Wolff ER, Sampaio RN, Gagliardi AR, et al. [Renal function in patients with mucocutaneous leishmaniasis treated with pentavalent antimony compounds]. Revista do Instituto de Medicina Tropical de Sao Paulo 1985;27(6):298-302. x-wiley/crsRef/14402836 [PMID: 3014634]
110. Vélez ID, Gilchrist K, Arbelaez MP, Rojas CA, Puerta JA, Antunes CM, et al. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Transactions of the Royal Society of Tropical Medicine and Hygiene 2005;99(8):593-8. [CENTRAL: CN-00521907] x-wiley/crsRef/14402838
111. Wortmann G, Scoot Miller R, Oster C, Jackson J, Aronson N. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clinical Infectious Diseases 2002;35(3):261-7. x-wiley/crsRef/3230825 [PMID: 12115091]
112. NCT00004755. Allopurinol, glucantime, or allopurinol/glucantime for cutaneous leishmaniasis in Brazil [Phase II randomized study of allopurinol versus glucantime versus allopurinol/glucantime for cutaneous leishmaniasis in Brazil]. clinicaltrials.gov/ct2/show/record/NCT00004755 (first received 25 February 2000). x-wiley/crsRef/3230831
113. NCT00111514. Study to evaluate the Leish-111F + MPL-SE vaccine in the treatment of mucosal leishmaniasis [A phase 1, randomized, double-blind, placebo-controlled, dose-escalating study to evaluate safety, tolerability, and immunogenicity of Leish-111f + MPL-SE vaccine in combination with pentavalent antimony in treatment of mucosal leishmaniasis]. clinicaltrials.gov/ct2/show/study/NCT00111514 (first received 23 May 2005). x-wiley/crsRef/3230833
114. NCT00111553. Study to evaluate the Leish-111F + MPL-SE vaccine in the treatment of cutaneous leishmaniasis [Randomized, double-blind, adjuvant- and placebo-controlled, dose-escalating study to evaluate safety, tolerability, and immunogenicity of Leish-111f + MPL-SE vaccine with meglumine antimoniate (glucantime) in cutaneous leishmaniasis]. clinicaltrials.gov/ct2/show/study/NCT00111553 (first received 24 May 2005). x-wiley/crsRef/3230835
115. NCT00317980. Safety and efficacy of low-dose pentavalent antimony for treatment of cutaneous leishmaniasis (Lowdosesb) [Phase IV randomized controlled clinical trial to evaluate the safety and efficacy of low-dose pentavalent antimony compared to the standard dose in patients with cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis]. clinicaltrials.gov/ct2/show/study/NCT00317980 (first received 25 April 2006). x-wiley/crsRef/3230845
116. NCT0973128. Reduced doses of antimony plus ranulocyte monocyte colony stimulating factor (GM-CSF) for cutaneous leishmaniasis (GMCSFSbv) [Reduced doses of antimony plus recombinant human GM-CSF compared with antimony in standard doses for cutaneous leishmaniasis: a randomized, single-blind, placebo-controlled, pilot study]. clinicaltrials.gov/ct2/show/study/NCT0973128 (first received 9 September 2009). x-wiley/crsRef/14402840
117. NCT01380301. Treatment of cutaneous leishmaniasis with a combination of miltefosine and antimony [Treatment of Bolivian cutaneous leishmaniasis with a combination of short courses of miltefosine and antimony]. clinicaltrials.gov/ct2/show/study/NCT01380301 (first received 27 June 2011). x-wiley/crsRef/14402842
118. NCT01380314. Oral miltefosine plus topical imiquimod to treat cutaneous leishmaniasis [Treatment of Bolivian cutaneous leishmaniasis with a combination of oral miltefosine plus topical imiquimod 5%]. clinicaltrials.gov/ct2/show/record/NCT01380314 (first received 27 June 2011). x-wiley/crsRef/14402844
119. NCT01464242. Add-on study of pentoxifylline in cutaneous leishmaniasis (GT) [Therapeutic gain of adding the immunomodulator pentoxifylline to the treatment of cutaneous leishmaniasis]. clinicaltrials.gov/ct2/show/record/NCT01464242 (first received 3 November 2011). x-wiley/crsRef/14402846
120. NCT03294161. Fourth-generation immucillin derivative DI4G associated therapy in cutaneous leishmaniasis [Transition-state analog inhibitor of human purine nucleoside phosphorylase as an adjunct in cutaneous leishmaniasis therapy: a randomized and controlled trial]. clinicaltrials.gov/ct2/show/study/NCT03294161 (first received 26 September 2017). x-wiley/crsRef/14402848
121. Silva SY, Rueda LC, Lopez M, Velez ID, Rueda-Clausen CF, Smith DJ, et al. Double blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis [NCT00317629]. Trials 2006;7:14. x-wiley/crsRef/14402850 [PMID: 16700912]
122. NCT00537953. Short course of miltefosine and antimony to treat cutaneous leishmaniasis in Bolivia [Efficacy and safety of a short course of the combination of miltefosine and antimony to treat cutaneous leishmaniasis in Bolivia]. clinicaltrials.gov/ct2/show/study/NCT00537953 (first received 2 October 2007). x-wiley/crsRef/3230853
123. NCT01301937. Low antimonial dosage in American mucosal leishmaniasis [Phase III clinical trial for mucosal or mucocutaneous leishmaniasis. Comparison between the standard and alternative antimonial schemes]. clinicaltrials.gov/ct2/show/study/NCT01301937 (first received 23 February 2011). x-wiley/crsRef/14402852
124. NCT02530697. The association of miltefosine and pentoxifylline to treat mucosal leishmaniasis: a clinical trial in Brazil. clinicaltrials.gov/ct2/show/study/NCT02530697 (first received 21 August 2015). x-wiley/crsRef/14402854
125. NCT02687971. Thermotherapy + a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World. clinicaltrials.gov/ct2/show/study/NCT02687971 (first received 23 February 2016). x-wiley/crsRef/14402856
126. NCT03023111. Miltefosine and GM-CSF in cutaneous leishmaniasis: a randomized and controlled trial. clinicaltrials.gov/ct2/show/NCT03023111 (first received 18 January 2017). x-wiley/crsRef/14402858
127. NCT03084952. Phase 2 trial to evaluate 18-methoxycoronaridine efficacy, safety and tolerability in cutaneous leishmaniasis patients. clinicaltrials.gov/ct2/show/study/NCT03084952 (first received 21 March 2017). x-wiley/crsRef/14402860
128. NCT03829917. Oral miltefosine plus topical paromomycin In American cutaneous leishmaniasis. clinicaltrials.gov/show/nct03829917 (first received 1 August 2019). x-wiley/crsRef/14402862
129. NCT04072874. Evaluation of the safety and clinical activity of Curaleish lotion and cream in the topical treatment of cutaneous leishmaniasis in Colombia. clinicaltrials.gov/ct2/show/NCT04072874 (first received 4 September 2019). x-wiley/crsRef/14402864
130. NTR2076. Treatment of cutaneous leishmaniasis with pentamidine isethionate in Suriname; a comparison study between two treatment regimes, 3 days vs 7 days [Clinical, parasitological and pharmaco-economical evaluation of a 3 days versus 7 days pentamidine isethionate regimen for cutaneous leishmaniasis in Suriname]. www.trialregister.nl/trialreg/admin/rctview.asp?TC=2076 (first received 25 September 2009). x-wiley/crsRef/14402866
131. PER-007-16. A randomized, open label multicenter study to determine the efficacy and safety of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World. www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevo.asp?ver=EN&numEc=007-16 (first received 5 July 2016). x-wiley/crsRef/14402868
132. RBR-5r93wn. Comparison of the effect and toxicity between two options for the treatment of Mucosal Leishmaniasis: miltefosin and Liposomal Anfotericin B. apps.who.int/trialsearch/Trial2.aspx?TrialID=RBR-5r93wn (first received 15 January 2018). x-wiley/crsRef/14402870
133. RBR-6mk5n4. Multicentre study evaluating the efficacy and safety of Intralesional administration of Meglumine Antimoniate compared to systemic treatment for cutaneous leishmaniasis. www.ensaiosclinicos.gov.br/rg/RBR-6mk5n4/ (first received 8 November 2017). x-wiley/crsRef/14402872
134. Abdeladhim M, Kamhawi S, Valenzuela JG. What's behind a sand fly bite? The profound effect of sand fly saliva on host hemostasis, inflammation and immunity. Infection, Genetics and Evolution 2014;28:691-703.
135. Alcais A, Abel L, David C, Torrez ME, Flandre P, Dedet JP. Risk factors for onset of cutaneous and mucocutaneous leishmaniasis in Bolivia. American Journal of Tropical Medicine and Hygiene 1997;57(1):79-84.
136. Alexander B, Agudelo LA, Navarro JF, Ruiz J F, Molina J, Aguilera G, et al. Relationship between coffee cultivation practices in Colombia and exposure to infection with Leishmania. Transactions of the Royal Society of Tropical Medicine and Hygiene 2009;103(12):1263-8.
137. Almeida RP, Brito J, Machado PL, De Jesus AR, Schriefer A, Guimaraes LH, et al. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. American Journal of Tropical Medicine and Hygiene 2005;73(1):79-81.
138. Almeida OL, Santos JB. Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review. Anais Brasileiros de Dermatologia 2011;86(3):497-506.
139. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLOS One 2012;7(5):e35671.
140. Alvar J, Croft S L, Kaye P, Khamesipour A, Sundar S, Reed SG. Case study for a vaccine against leishmaniasis. Vaccine 2013;31(Suppl 2):B244-9.
141. Amato VS, Tuon FF, Siqueira AM, Nicodemo AC, Neto VA. Treatment of mucosal leishmaniasis in Latin America: systematic review. American Journal of Tropical Medicine and Hygiene 2007;77(2):266-74.
142. Ampuero J, Macedo V, Marsden P. Clinical findings of tegumentary leishmaniasis in children under five years of age in an endemic area of Leishmania (Viannia) braziliensis. Revista da Sociedade Brasileira de Medicina Tropical 2006;39(1):22-6.
143. Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos-Cuentas A, et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clinical Infectious Diseases 2007;44(12):1549-54.
144. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clinical Infectious Diseases 2016;63(12):e202-64.
145. Badaro R, Lobo I, Nakatani M, Muinos A, Netto EM, Coler RN, et al. Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: a case report. Brazilian Journal of Infectious Diseases 2001;5(4):223-32.
146. Barral A, Costa JM, Bittencourt AL, Barral-Netto M, Carvalho EM. Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects. International Journal of Dermatolology 1995;34(7):474-9.
147. Baryza MJ, Baryza GA. The Vancouver Scar Scale: an administration tool and its interrater reliability. Journal of Burn Care & Rehabilitation 1995;16(5):535-38.
148. Beaumier CM, Gillespie PM, Hotez PJ, Bottazzi ME. New vaccines for neglected parasitic diseases and dengue. Translational Research 2013;162(3):144-55.
149. Becker I, Volkow P, Velasco-Castrejon O, Salaiza-Suazo N, Berzunza-Cruz M, Dominguez JS, et al. The efficacy of pentamidine combined with allopurinol and immunotherapy for the treatment of patients with diffuse cutaneous leishmaniasis. Parasitology Research 1999;85(3):165-70.
150. Berman JD, Neva FA. Effect of temperature on multiplication of Leishmania amastigotes within monocyte-derived macrophages in vitro. American Journal of Tropical Medicine and Hygiene 1981;30:318-21.
151. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Neglected Tropical Diseases 2008;2(10):e313.
152. Beyrer C, Villar JC, Suwanvanichkij V, Singh S, Baral SD, Mills EJ. Neglected diseases, civil conflicts, and the right to health. Lancet 2007;370(9587):619-27.
153. Biagi F. Synthesis of 70 case histories of cutaneous leishmaniasis of Mexico (ulcer of the chicle gatherers). Medicina (Mex) 1953;33(682):385-96.
154. Bigby M, Williams H. Appraising systematic reviews and meta-analyses. Archives of Dermatology 2003;139(6):795-8.
155. Boggild AK, Miranda-Verastegui C, Espinosa D, Arevalo J, Martinez-Medina D, Llanos-Cuentas A, et al. Optimization of microculture and evaluation of miniculture for the isolation of Leishmania parasites from cutaneous lesions in Peru. American Journal of Tropical Medicine and Hygiene 2008;79(6):847-52.
156. Boggild AK, Ramos AP, Espinosa D, Valencia BM, Veland N, Miranda-Verastegui C, et al. Clinical and demographic stratification of test performance: a pooled analysis of five laboratory diagnostic methods for American cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2010;83(2):345-50.
157. Bomfim G, Andrade BB, Santos S, Clarencio J, Barral-Netto M, Barral A. Cellular analysis of cutaneous leishmaniasis lymphadenopathy: insights into the early phases of human disease. American Journal of Tropical Medicine and Hygiene 2007;77(5):854-9.
158. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS One 2017;12(9):e0184777.
159. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. Journal of Infectious Diseases 1999;179(6):1485-94.
160. Cardona-Arias JA, Vélez ID, Lopez-Carvajal L. Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials. PLOS One 2015;10(5):e0122569.
161. Carvalho AM, Cristal JR, Muniz AC, Carvalho LP, Gomes R, Miranda JC, et al. Interleukin 10-dominant immune response and increased risk of cutaneous leishmaniasis after natural exposure to lutzomyia intermedia sand flies. Journal of Infectious Diseases 2015;212(1):157-65.
162. Consigli J, Danielo C, Gallerano V, Papa M, Guidi A. Cutaneous leishmaniasis: successful treatment with itraconazole. International Journal of Dermatolology 2006;45(1):46-9.
163. Costa JM, Marsden PD, Llanos-Cuentas EA, Netto EM, Carvalho EM, Barral A, et al. Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases. Journal of Tropical and Medicine Hygiene 1986;89(6):319-23.
164. Cota GF, De Sousa MR, Fereguetti TO, Saleme PS, Alvarisa TK, Rabello A. The cure rate after placebo or no therapy in American cutaneous leishmaniasis: a systematic review and meta-analysis. PLOS One 2016;11(2):e0149697.
165. Veritas Health Innovation Covidence. Melbourne, Australia: Veritas Health Innovation, accessed prior to 9 April 2019. Available at covidence.org.
166. Cummings AM, Hedge JL, Laskey J. Ketoconazole impairs early pregnancy and the decidual cell response via alterations in ovarian function. Fundamental and Applied Toxicology 1997;40(2):238-46.
167. Cupolillo E, Grimaldi G Jr, Momen H. A general classification of New World Leishmania using numerical zymotaxonomy. American Journal of Tropical Medicine and Hygiene 1994;50(3):296-311.
168. Cupolillo E, Aguiar Alves F, Brahim LR, Naiff MF, Pereira LO, Oliveira-Neto MP, et al. Recent advances in the taxonomy of the New World leishmanial parasites. Medical Microbiology and Immunology 2001;190(1-2):57-60.
169. Dantas ML, Oliveira JM, Carvalho L, Passos ST, Queiroz A, Guimaraes LH, et al. Comparative analysis of the tissue inflammatory response in human cutaneous and disseminated leishmaniasis. Memórias do Instituto Oswaldo Cruz 2014;109(2):202-9.
170. Davies CR, Llanos-Cuentas EA, Campos P, Monge J, Villaseca P, Dye C. Cutaneous leishmaniasis in the Peruvian Andes: risk factors identified from a village cohort study. American Journal of Tropical Medicine and Hygiene 1997;56(1):85-95.
171. Davies CR, Reithinger R, Campbell-Lendrum D, Feliciangeli D, Borges R, Rodriguez N. The epidemiology and control of leishmaniasis in Andean countries. Cadernos de Saude Publica / Ministerio da Saude, Fundacao Oswaldo Cruz, Escola Nacional de Saude Publica 2000;16(4):925-50.
172. De Lima H, Rodriguez N, Feliciangeli MD, Barrios MA, Sosa A, Agrela I, et al. Cutaneous leishmaniasis due to Leishmania chagasi/Le. infantum in an endemic area of Guarico State, Venezuela. Transactions of the Royal Society of Tropical Medicine and Hygiene 2009;103(7):721-6.
173. De Macedo-Silva ST, Urbina JA, De Souza W, Rodrigues JC. In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis. PLOS One 2013;8(12):e83247.
174. Deeks JJ, Higgins JP, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). The Cochrane Collaboration, 2019. Available from www.training.cochrane.org/handbook.
175. Duthie MS, Raman VS, Piazza FM, Reed SG. The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine 2012;30(2):134-41.
176. Edwards L. Imiquimod in clinical practice. Journal of the American Academy of Dermatology 2000;43(1 Pt 2):S12-7.
177. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629–34.
178. Enk CD, Nasereddin A, Alper R, Dan-Goor M, Jaffe CL, Wulf HC. Cutaneous leishmaniasis responds to daylight-activated photodynamic therapy: proof of concept for a novel self-administered therapeutic modality. British Journal of Dermatology 2015;172(5):1364-70.
179. Evangelou G, Krasagakis K, Giannikaki E, Kruger-Krasagakis S, Tosca A. Successful treatment of cutaneous leishmaniasis with intralesional aminolevulinic acid photodynamic therapy. Photodermatology, Photoimmunology and Photomedicine 2011;27(5):254-6.
180. Food And Drug Administration Drug Safety Communication. Use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants. www.fda.gov/Drugs/DrugSafety/ucm266030.htm (accessed prior to 23 January 2019).
181. Food And Drug Administration Drug Safety Communication. Nizoral (ketoconazole) oral tablets: Potentially fatal liver injury, risk of drug interactions and adrenal gland problems. www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-limits-usage-nizoral-ketoconazole-oral-tablets-due-potentially (accessed 09 August 2020).
182. Food And Drug Administration Drug Safety Communication. Sporanox (itraconazole) Oral Solution - Detailed view: Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). www.accessdata.fda.gov/drugsatfda_docs/label/2012/020657s027lbl.pdf (accessed prior to 23 January 2019).
183. Food And Drug Administration Drug Safety Communication. FDA evaluating study examining use of oral fluconazole (Diflucan) in pregnancy. www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-study-examining-use-oral-fluconazole-diflucan-pregnancy (accessed prior to 23 January 2019).
184. Fernandez OL, Diaz-Toro Y, Ovalle C, Valderrama L, Muvdi S, Rodriguez I, et al. Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia. PLOS Neglected Tropical Diseases 2014;8(5):e2871.
185. Fontenele e Silva JS, Galvao TF, Pereira MG, Silva MT. Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence. Revista da Sociedade Brasileira de Medicina Tropical 2013;46(6):669-77.
186. Fraga J, Veland N, Montalvo AM, Praet N, Boggild AK, Valencia BM, et al. Accurate and rapid species typing from cutaneous and mucocutaneous leishmaniasis lesions of the New World. Diagnostic Microbiology and Infectious Disease 2012;74(2):142-50.
187. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Revews of Infectious Diseases 1990;12(2):308-29.
188. Galvão EL, Rabello A, Cota GF. Efficacy of azole therapy for tegumentary leishmaniasis: a systematic review and meta-analysis. PLOS One 2017;12(10):e0186117.
189. Galvão EL, Pedras MJ, Cota GF, Simões TC, Rabello A. Development and initial validation of a cutaneous leishmaniasis impact questionnaire. PLOS One 2018;13(8):e0203378.
190. Galvão EL, Pedras MJ, Cota GF, Rabello A, Simões TC. How cutaneous leishmaniasis and treatment impacts in the patients' lives: a cross-sectional study. PLOS One 2019;14(1):e0211374.
191. Gomes CM, Mazin SC, Santos ER, Cesetti MV, Bachtold GA, Cordeiro JH, et al. Accuracy of mucocutaneous leishmaniasis diagnosis using polymerase chain reaction: systematic literature review and meta-analysis. Memórias do Instituto Oswaldo Cruz 2015;110(2):157-65.
192. González U, Pinart M, Reveiz L, Rengifo-Pardo M, Tweed J, Macaya A, et al. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clinical Infectious Diseases 2010;51(4):409-19.
193. González U, Pinart M, Sinclair D, Firooz A, Enk C, Vélez ID, et al. Vector and reservoir control for preventing leishmaniasis. Cochrane Database of Systematic Reviews 2015, Issue 8. Art. No: CD008736. [DOI: 10.1002/14651858.CD008736.pub2]
194. Graca GC, Volpini AC, Romero GA, Oliveira Neto MP, Hueb M, Porrozzi R, et al. Development and validation of PCR-based assays for diagnosis of American cutaneous leishmaniasis and identification of the parasite species. Memórias do Instituto Oswaldo Cruz 2012;107(5):664-74.
195. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
196. Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis: clinical perspectives. Journal of the American Academy of Dermatology 2015;73(6):897-908; quiz 909-10.
197. Hashiguchi Y, Gomez EL, Kato H, Martini LR, Velez LN, Uezato H. Diffuse and disseminated cutaneous leishmaniasis: clinical cases experienced in Ecuador and a brief review. Tropical Medicine and Health 2016;44:2.
198. Heras-Mosteiro J, Monge-Maillo B, Pinart M, Lopez Pereira P, Reveiz L, Garcia-Carrasco E, et al. Interventions for Old World cutaneous leishmaniasis. Cochrane Database of Systematic Reviews 2017, Issue 12. Art. No: CD005067. [DOI: 10.1002/14651858.CD005067.pub5]
199. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
200. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
201. Hoeltzenbein M, Stieler K, Panse M, Wacker E, Schaefer C. Allopurinol use during pregnancy - outcome of 31 prospectively ascertained cases and a phenotype possibly indicative for teratogenicity. PLOS One 2013;8(6):e66637.
202. Jin G, Wong ST. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discovery Today 2014;19(5):637-44.
203. Karimkhani C, Wanga V, Coffeng LE, Naghavi P, Dellavalle RP, Naghavi M. Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013. Lancet Infectious Diseases 2016;16(5):584-91.
204. Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLOS Neglected Tropical Diseases 2009;3(2):e381.
205. Lainson R, Shaw JJ, Silveira FT, De Souza AA, Braga RR, Ishikawa EA. The dermal leishmaniases of Brazil, with special reference to the eco-epidemiology of the disease in Amazonia. Memórias do Instituto Oswaldo Cruz 1994;89(3):435-43.
206. Lee N, Bertholet S, Debrabant A, Muller J, Duncan R, Nakhasi HL. Programmed cell death in the unicellular protozoan parasite Leishmania. Cell Death Differentiation 2002;9(1):53-64.
207. Lessa HA, Lessa MM, Guimaraes LH, Lima CM, Arruda S, Machado PR, et al. A proposed new clinical staging system for patients with mucosal leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 2012;106(6):376-81.
208. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, Miranda-Verastegui C, Santamaria-Castrellon G, Ramirez L, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clinical Infectious Diseases 2008;46(2):223-31.
209. Lopez L, Robayo M, Vargas M, Vélez ID. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials 2012;13:58.
210. López-Carvajal L, Cardona-Arias JA, Zapata-Cardona MI, Sánchez-Giraldo V, Vélez ID. Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials. BMC Infectous Diseases 2016;16:360. [DOI: 10.1186/s12879-016-1663-3]
211. Machado PR, Rosa ME, Guimaraes LH, Prates FV, Queiroz A, Schriefer A, et al. Treatment of disseminated leishmaniasis with liposomal amphotericin B. Clinical Infectious Diseases 2015;61(6):945-9.
212. Mansueto P, Seidita A, Vitale G, Cascio A. Leishmaniasis in travelers: a literature review. Travel Medicine and Infectious Disease 2014;12(6 Pt A):563-81.
213. Marsden PD. Current concepts in parasitology. Leishmaniasis. New England Journal of Medicine 1979;300(7):350-2.
214. Marsden PD. Mucosal leishmaniasis due to Leishmania (Viannia) braziliensis L(V)b in Tres Bracos, Bahia-Brazil. Revista da Sociedade Brasileira de Medicina Tropical 1994;27(2):93-101.
215. Marsden PD, Lessa HA, Oliveira MR, Romero GA, Marotti JG, Sampaio RN, et al. Clinical observations of unresponsive mucosal leishmaniasis. American Journal of Tropical Medicine and Hygiene 1998;59(4):543-5.
216. Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: past, present and future. Current Medicinal Chemistry 2007;14(10):1153-69.
217. Modabber F, Buffet PA, Torreele E, Milon G, Croft SL. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biology and Disease 2006;6:3.
218. Mondragon-Shem K, Al-Salem WS, Kelly-Hope L, Abdeladhim M, Al-Zahrani MH, Valenzuela JG, et al. Correction: Severity of Old World cutaneous leishmaniasis Is influenced by previous exposure to sandfly bites in Saudi Arabia. PLoS Neglected Tropical Diseases 2015;9(12):e0004294.
219. Monteiro WM, Neitzke-Abreu HC, Ferreira ME, Melo GC, Barbosa Md, Lonardoni MV, et al. Population mobility and production of American tegumentary leishmaniasis in the State of Parana, southern Brazil. Revista da Sociedade Brasileira de Medicina Tropical 2009;42(5):509-14.
220. Neto VL, Véras MM. American tegumentary leishmaniasis: fluconazole therapy. Revista Brasileira de Medicina de Família e Comunidade 2006;2(7):228-34.
221. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Tropica 2011;118(2):87-96.
222. Oliveira MB, Calixto G, Graminha M, Cerecetto H, Gonzalez M, Chorilli M. Development, characterization, and in vitro biological performance of fluconazole-loaded microemulsions for the topical treatment of cutaneous leishmaniasis. BioMed Research International 2015;2015:396894.
223. Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, et al. Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLOS Neglected Tropical Diseases 2013;7(3):e2130.
224. Olliaro P, Grogl M, Boni M, Carvalho EM, Chebli H, Cisse M, et al. Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation. PLOS Neglected Tropical Diseases 2018;12(1):e0006141.
225. Osorio LE, Castillo CM, Ochoa MT. Mucosal leishmaniasis due to Leishmania (Viannia) panamensis in Colombia: clinical characteristics. American Journal of Tropical Medicine and Hygiene 1998;59(1):49-52.
226. Page MJ, Higgins JP, Sterne JA. Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). The Cochrane Collaboration, 2019. Available from www.training.cochrane.org/handbook.
227. Pan American Health Organization. Leishmaniasis in the Americas: Treatment recommendations [Leishmaniasis en las Américas. recomendaciones para el tratamiento]. www.paho.org/hq/index.php?option=com_topics&view=rdmore&cid=6123&item=leishmaniasis&cat=scientific_technical&type=guidelines-6123&Itemid=40754&lang=en (accessed prior to 23 January 2019). [ISBN: 978-92-75-11752-1]
228. Pan American Health Organization. Leishmaniasis in the Americas: Treatment recommendations. www.paho.org/hq/index.php?option=com_topics&view=rdmore&cid=6123&item=leishmaniasis&cat=scientific_technical&type=guidelines-6123&Itemid=40754&lang=en (accessed prior to 14 July 2020).
229. Pan American Health Organization. Leishmaniasis: Epidemiological Report in the Americas. iris.paho.org/xmlui/bitstream/handle/123456789/50505/Leishreport2019_eng.pdf (accessed prior to 25 February 2020).
230. Pan American Health Organization. Manual of Procedures for Leishmaniases Surveillance and Control in the Americas. Washington, D.C: PAHO, 2019. [ISBN: 9789275120637]
231. Perez-Florez M, Ocampo CB, Valderrama-Ardila C, Alexander N. Spatial modeling of cutaneous leishmaniasis in the Andean region of Colombia. Memórias do Instituto Oswaldo Cruz 2016;111(7):433-42. [DOI: 10.1590/0074-02760160074]
232. Peterson AT, Shaw J. Lutzomyia vectors for cutaneous leishmaniasis in Southern Brazil: ecological niche models, predicted geographic distributions, and climate change effects. International Journal of Parasitology 2003;33(9):919-31.
233. Ponte-Sucre A. Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplastid Biology and Disease 2003;2(1):14.
234. Prestes SR, Guerra JA, Romero GA, Magalhaes LK, Santana RA, Maciel MG, et al. Polymerase chain reaction-based method for the identification of Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in mucosal tissues conserved in paraffin. Revista da Sociedade Brasileira de Medicina Tropical 2015;48(5):555-9.
235. Ramos H, Valdivieso E, Gamargo M, Dagger F, Cohen BE. Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. Journal of Membrane Biology 1996;152(1):65-75.
236. Reed SG, Coler RN, Mondal D, Kamhawi S, Valenzuela JG. Leishmania vaccine development: exploiting the host-vector-parasite interface. Expert Review of Vaccines 2016;15(1):81-90.
237. Reveiz L, Maia-Elkhoury AN, Nicholls RS, Romero GA, Yadon ZE. Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update. PLOS One 2013;8(4):e61843.
238. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
239. Rojas CA, Weigle KA, Barrera L, Collazos C. Surveillance and screening of American cutaneous leishmaniasis by Colombian primary health care workers using a clinical prediction rule. Transactions of the Royal Society of Tropical Medicine and Hygiene 2002;96(4):405-10.
240. Romero GA, Guerra MV, Paes MG, Macedo VO. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. American Journal of Tropical Medicine and Hygiene 2001;65(5):456-65.
241. Romero GA, Vinitius De Farias Guerra M, Gomes Paes M, De Oliveira Macedo V. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: clinical findings and diagnostic approach. Clinical Infectious Diseases 2001;32(9):1304-12.
242. Romero GA, De la Gloria Orge M, De Farias Guerra MV, Paes MG, De Oliveira Macedo V, De Carvalho EM. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil. Acta Tropica 2005;93(1):49-56.
243. Sacks DL, Barral A, Neva F. Thermosensitivity patterns of Old vs. New World cutaneous strains of Leishmania growing within mouse peritoneal macrophages in vitro. American Journal of Tropical Medicine and Hygiene 1983;32(2):300-4.
244. Salaiza-Suazo N, Volkow P, Tamayo R, Moll H, Gillitzer R, Perez-Torres A, et al. Treatment of two patients with diffuse cutaneous leishmaniasis caused by Leishmania mexicana modifies the immunohistological profile but not the disease outcome. Tropical Medicine and International Health 1999;4(12):801-11.
245. Sands M, Kron MA, Brown RB. Pentamidine: a review. Reviews of Infectious Diseases 1985;7(5):625-34.
246. Santrich C, Segura I, Arias AL, Saravia NG. Mucosal disease caused by Leishmania braziliensis guyanensis. American Journal of Tropical Medicine and Hygiene 1990;42(1):51-5.
247. Savioli L, Engels D, Daumerie D, Jannin J, Alvar J, Asiedu K, et al. Response from Savioli and colleagues from the Department of Neglected Tropical Diseases, World Health Organization. PLOS Medicine 2006;3(6):e283.
248. Schonian G, Mauricio I, Cupolillo E. Is it time to revise the nomenclature of Leishmania? Trends in Parasitology 2010;26(10):466-9.
249. Sereno D, Holzmuller P, Mangot I, Cuny G, Ouaissi A, Lemesre JL. Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrobial Agents and Chemotherapy 2001;45(7):2064-9.
250. Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998;351(9115):1540-3.
251. Shaw JJ. Animal reservoirs of Leishmania in different ecological situations and their importance in the epidemiology of the disease. Memórias do Instituto Oswaldo Cruz 1988;83(Suppl 1):486-90.
252. Sousa AQ, Frutuoso MS, Moraes EA, Pearson RD, Pompeu MM. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clinical Infectious Diseases 2011;53(7):693-5.
253. Sudhandiran G, Shaha C. Antimonial-induced increase in intracellular Ca2+ through non-selective cation channels in the host and the parasite is responsible for apoptosis of intracellular Leishmania donovani amastigotes. Journal of Biological Chemistry 2003;278(27):25120-32.
254. Sundar S, Chatterjee M. Visceral leishmaniasis-current therapeutic modalities. Indian Journal of Medicine Research 2006;123(3):345-52.
255. Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opinion on Investigational Drugs 2008;17(5):787-94.
256. Tojal da Silva AC, Cupolillo E, Volpini AC, Almeida R, Romero GA. Species diversity causing human cutaneous leishmaniasis in Rio Branco, state of Acre, Brazil. Tropical Medicine & International Health 2006;11(9):1388-98.
257. Toledo AC Jr, Da Silva RE, Carmo RF, Amaral TA, Luz ZM, Rabello A. Assessment of the quality of life of patients with cutaneous leishmaniasis in Belo Horizonte, Brazil, 2009-2010. A pilot study. Transactions of the Royal Society of Tropical Medicine 2013;107(5):335-6.
258. Tracy JW, Webster LT Jr. Drugs used in the chemotherapy of protozoal infections. In: Hardman JG, Limbird LE, Gilman AG, editors(s). The Pharmacological Basis of Therapeutics. 10th edition. New York: McGraw-Hill, 2001.
259. Turetz ML, Machado PR, Ko AI, Alves F, Bittencourt A, Almeida RP, et al. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. Journal of Infectious Diseases 2002;186(12):1829-34.
260. Verma NK, Dey CS. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrobial Agents and Chemotherapy 2004;48(8):3010-5.
261. Weigle KA, De Davalos M, Heredia P, Molineros R, Saravia NG, D'Alessandro A. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. American Journal of Tropical Medicine and Hygiene 1987;36(3):489-96.
262. Weigle KA, Valderrama L, Arias AL, Santrich C, Saravia NG. Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction and sensitization. American Journal of Tropical Medicine and Hygiene 1991;44(3):260-71.
263. Weigle KA, Escobar M, Arias AL, Martinez F, Rojas C. A clinical prediction rule for American cutaneous leishmaniasis in Colombia. International Journal of Epidemiology 1993;22(3):548-58.
264. World Health Organization. Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. apps.who.int/iris/handle/10665/44412 (accessed prior to 23 January 2019).
265. Wortmann G, Zapor M, Ressner R, Fraser S, Hartzell J, Pierson J, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2010;83(5):1028-33.
266. Yadon ZE, Rodrigues LC, Davies CR, Quigley MA. Indoor and peridomestic transmission of American cutaneous leishmaniasis in northwestern Argentina: a retrospective case-control study. American Journal of Tropical Medicine and Hygiene 2003;68(5):519-26.
267. Yang YG, Zou XB, Zhao H, Zhang YJ, Li HJ. Photodynamic therapy of condyloma acuminata in pregnant women. Chinese Medical Journal (Engl) 2012;125(16):2925-8.
268. Zajtchuk JT, Casler JD, Netto EM, Grogl M, Neafie RC, Hessel CR, et al. Mucosal leishmaniasis in Brazil. Laryngoscope 1989;99(9):925-39.
269. González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J. Interventions for mucocutaneous leishmaniasis. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No: CD004834. [DOI: 10.1002/14651858.CD004834]
270. González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No: CD004834. [DOI: 10.1002/14651858.CD004834.pub2]